Skip to content
  • Myriad Genetics shares retreat on Court decision

    USA Today - 06/13/2013

    Investors initially pushed the stock up by focusing on the bright side of the ruling. The Supreme Court said Myriad does have the legal right to patent forms of human’s genetic code that can be predictive of who might contract breast or ovarian cancer, says Michael Bennett, professor of law at Northeastern University. Investors may have been expecting the company to lose all its claims, so the fact were were upheld was a comfort, he says.

     

  • Cookies on Northeastern sites

    This website uses cookies and similar technologies to understand your use of our website and give you a better experience. By continuing to use the site or closing this banner without changing your cookie settings, you agree to our use of cookies and other technologies. To find out more about our use of cookies and how to change your settings, please go to our Privacy Statement.